The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients

Abstract Background The role of carcinoembryonic antigen (CEA) change patterns in tumor response and long-term outcome is unclear. This study aimed to investigate the correlation between changes in CEA levels and tumor response as a potential prognostic model. Methods CEA levels were determined from...

Full description

Bibliographic Details
Main Authors:	Ping Yu, Mingyi Zhou, Jinglei Qu, Lingyu Fu, Xuedan Li, Ruimei Cai, Bo Jin, Yuee Teng, Jing Liu, Jing Shi, Jingdong Zhang
Format:	Article
Language:	English
Published:	BMC 2018-11-01
Series:	BMC Cancer
Subjects:	CEA change Tumor response Progression Metastatic colorectal cancer
Online Access:	http://link.springer.com/article/10.1186/s12885-018-4987-0

Similar Items

Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study
by: Jinjia Chang, et al.
Published: (2019-01-01)

The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels
by: Xie HL, et al.
Published: (2019-08-01)

CEA as a prognostic index in colorectal cancer
by: Nora Manoukian Forones, et al.

Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice
by: Saridaki Zenia, et al.
Published: (2014-12-01)

Association between Primary Perioperative CEA Ratio, Tumor Site, and Overall Survival in Patients with Colorectal Cancer
by: Thomas A. Odeny, et al.
Published: (2020-11-01)

Effect of UBE2Q on BECN and CEA Protein in Colorectal Cancer Cells
by: Niloofar Boroumand
Published: (2018-12-01)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
by: Martin S. Schulz, et al.
Published: (2022-03-01)

The diagnostic value of blood level of CEA and CA15-3 tumor markers in breast tumor with axillary lymph node metastases
by: M. Gahremani, et al.
Published: (2007-01-01)

Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
by: Sara Lonardi, et al.
Published: (2022-09-01)

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
by: Gouvas Nikolaos, et al.
Published: (2019-07-01)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
by: Kimberly A. Lowe, et al.
Published: (2019-05-01)

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
by: Ian Chau, et al.
Published: (2020-03-01)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
by: Beatrice Borelli, et al.
Published: (2022-10-01)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

CEA, CA19-9 & A-FP as tumor markers for colorectal carcinoma
by: Ansam A. AL-Bayatti, et al.
Published: (2006-04-01)

A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
by: Akshit Chitkara, et al.
Published: (2023-09-01)

The prognostic value of preoperative serum CA724 for CEA-normal colorectal cancer patients
by: Jiaan Kuang, et al.
Published: (2020-04-01)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
by: Annabel H. S. Alig, et al.
Published: (2022-01-01)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
by: Bo Song, et al.
Published: (2023-09-01)

Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study
by: Zhenhui Li, et al.
Published: (2022-09-01)

Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
by: Maria Alessandra Calegari, et al.
Published: (2021-04-01)

Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
by: Mingyi Zhou, et al.
Published: (2016-11-01)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
by: Kaisa Lehtomäki, et al.
Published: (2021-08-01)

Multiple myeloma presenting as CEA-producing rectal cancer
by: Giampaolo Talamo
Published: (2010-03-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Predictive Value of Albumin-Bilirubin Score Combined with Liver Function Index and CEA for Liver Metastasis of Colorectal Cancer
by: FAN Wanli, et al.
Published: (2024-01-01)

High-density controlled environment agriculture (CEA-HD) air distribution optimization using computational fluid dynamics (CFD)
by: Gilbert Larochelle Martin, et al.
Published: (2024-12-01)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
by: Seung E. Cha, et al.
Published: (2021-01-01)

Comparison of chemiluminescent microparticle immunoassay (CMIA) with electrochemiluminescence immunoassay (ECLIA) for Carcinoembryonic antigen (CEA)
by: Nafija Serdarevic, et al.
Published: (2018-09-01)

Preoperative CRP(−)/CEA(−)/CA19-9(−)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence
by: Mitsunori Ushigome, et al.
Published: (2022-10-01)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
by: Kaisa Lehtomäki, et al.
Published: (2023-04-01)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>
by: Jen-Hao Yeh, et al.
Published: (2021-12-01)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
by: Rossi L, et al.
Published: (2013-11-01)

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
by: Leilani Lakemeyer, et al.
Published: (2021-03-01)

Determination of Cancer Antigen CA15-3 and Carcino Embryonic Antigen CEA concentration as Tumor Markers in Patients with Stomach and Colorectal cancers.
by: Rana. K. AL-saady, et al.
Published: (2012-10-01)

Is Adjuvant Chemotherapy Worthwhile After Radical Resection for Single Lung Metastasis From Colorectal Cancer? A Multicentric Analysis Evaluating the Risk of Recurrence
by: Cristian Rapicetta, et al.
Published: (2019-08-01)

The Effects of Smoke of Waterpipe and Immobilization Stress on Serum Level of CEA in Female Rats
by: Rahim Ahmadi, et al.
Published: (2013-09-01)

The Effects of Smoke of Waterpipe and Immobilization Stress on Serum Level of CEA in Female Rats
by: Rahim Ahmadi, et al.
Published: (2013-09-01)

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
by: Mesti Tanja, et al.
Published: (2023-03-01)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
by: Yiyi Zhang, et al.
Published: (2021-01-01)